Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,596 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Allogeneic Transplant Clear all

Conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Leucovorin Calcium, Lumbar Puncture, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate, X-Ray Imaging; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 30 Years to 70 Years
Enrollment: 488 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 531
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more

Conditions: Cytomegalovirus Infection
Interventions: mRNA-1647, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • St Louis, Missouri • Seattle, Washington

Conditions: Cell Transplantation
Interventions: Medical Chart Review, Monitoring Device, Physical Therapy; Other · Device · Procedure
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Leukemia, Lymphoma
Interventions: therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 19
States / cities: Denver, Colorado • Newark, Delaware • Orlando, Florida + 15 more

Conditions: Distress, Hematopoietic Stem Cell Transplantation
Interventions: Problem Solving Education; Behavioral
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bone Marrow Failure, Hemoglobinopathies, Primary Immune Deficiency (PID), Autoimmune Cytopenia, Immune Dysregulation, Hemophagocytic Lymphohistiocytosis (HLH), Non Malignant Disorders
Interventions: ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs; Biological
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 6 Months to 50 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Type 1 Diabetes Mellitus
Interventions: Allogeneic Pancreatic Islet Cells, Antithymocyte globulin, Daclizumab, Rituximab, Sirolimus; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Recurrent Acute Myeloid Leukemia
Interventions: Venetoclax, Decitabine, Cedazuridine, Bone Marrow Aspiration and Biopsy, Biospecimen Collection; Drug · Procedure
Lead sponsor: Sanjay Mohan; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Inherited Metabolic Storage Diseases
Interventions: CAMPATH-1H, Anti-CD45, FK506, Fludarabine; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Hematological Malignancies
Interventions: Allogeneic T cell progenitors, cultured ex-vivo; Biological
Lead sponsor: Smart Immune SAS; Industry
Eligibility: Not listed
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Graft Versus Host Disease, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Waldenstrom Macroglobulinemia
Interventions: Cyclosporine, Mycophenolate Mofetil, Pentostatin, Therapeutic Allogeneic Lymphocytes; Drug · Biological
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 4
States / cities: Salt Lake City, Utah • Seattle, Washington

Conditions: Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Chronic, AML
Interventions: Donor Lymphocyte Infusion, Induction Chemotherapy; Procedure · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 1 Year to 70 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Stress, Psychological, Caregivers
Interventions: Stress reduction intervention; Other
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lymphoma, Leukemia
Interventions: Zevalin Radioimmunotherapy, Rituximab, Fludarabine, Cyclophosphamide, Allogeneic Stem Cell Transplantation; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Invasive Aspergillosis, Invasive Pulmonary Aspergillosis
Interventions: Investigational Agent: VL-2397, Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B; Drug
Lead sponsor: Vical; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 11
States / cities: Birmingham, Alabama • La Jolla, California • Sacramento, California + 8 more

Conditions: Hematopoietic/Lymphoid Cancer
Interventions: brentuximab vedotin, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 12 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Blood Stem Cell Transplant Failure, Leukemia, Hematologic Malignancies
Interventions: Cyclophosphamide, Fludarabine, Melphalan, Mesna, Rituximab, Stem Cell Transplantation, Thiotepa, Tacrolimus, Mycofenolate mofetil, G-CSF; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 75 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions: BPX-501 dose 1, Rimiducid, BPX-501 dose 2, BPX-501 dose 3, BPX-501 dose 4, SCT; Biological · Drug · Procedure
Lead sponsor: Bellicum Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2032
U.S. locations: 8
States / cities: Atlanta, Georgia • Buffalo, New York • New York, New York + 4 more

Conditions: Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome, Paroxysmal Nocturnal Hemoglobinuria, Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
Interventions: Systematic chemotherapy and antibodies, Allogeneic stem cell transplantation, Miltenyi CliniMACS; Drug · Procedure · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 21 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Hematologic Malignancies, Bone Marrow Transplant Rejection
Interventions: allogeneic hematopoietic stem cell transplantation; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fanconi Anemia, Severe Aplastic Anemia
Interventions: CAMPATH-1H, Anti-CD45, Fludarabine, Stem cell infusion; Biological · Drug · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Allogeneic Hematopoietic Cell Transplantation
Interventions: TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT); Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Multiple Myeloma
Interventions: Bortezomib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Immunosuppression, Stem Cell Transplant, Bone Marrow Transplant
Interventions: Tacrolimus; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

Prescribed Physical Activity in Improving Sleep and Physical Performance in Patients Undergoing Stem Cell Transplant

Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL

Problem-Solving Education for Caregivers and Patients During Stem Cell Transplant

Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases

B-Lymphocyte Immunotherapy in Islet Transplantation

Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases

Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

Post Transplant Donor Lymphocyte Infusion

Effectiveness of a Stress Reduction Intervention in Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients

Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies

Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia

TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders

Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma

Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients